[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fOQMCnPYgY4MDqxuV9e0lmimrtG6YFb7idQyTFhwUApY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"The Methodist Hospital Research Institute",[4],147,false,59,4,13137,54,57,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Prostatic Neoplasms",8,{"name":18,"count":19},"Breast Cancer",7,{"name":21,"count":22},"Carcinoma, Renal Cell",6,{"name":24,"count":25},"Neurogenic Bladder",5,{"name":27,"count":9},"Overactive Bladder",{"name":29,"count":9},"Alzheimer Disease",{"name":31,"count":9},"Healthy",{"name":33,"count":34},"Multiple Sclerosis",3,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT01913106","HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer","2018-12","HSV-tk +Valacyclovir in Combination with Brachytherapy",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04055623","T-regulatory Cells in ALS","2022-05-31","Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05831774","IO Vancomycin in TSA","2024-07-15","Intervention - Intraosseous (IO) administration of vancomycin",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03820141","Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer","2024-10-30","Durvalumab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04665310","Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant","2025-07-31","Envarsus XR",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05241340","Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer","2025-08-01","Sasanlimab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04020809","Neoadjuvant Atezolizumab in Cutaneous Melanoma","2025-10-01","Atezolizumab",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT03478215","Mesenchymal Stromal Cells in Living Donor Kidney Transplantation","2025-12","Mesenchymal Stromal Stem Cells (MSCs)",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT03742245","Olaparib in Combination With Vorinostat in Patients With Relapsed\u002FRefractory and\u002For Metastatic Breast Cancer","2025-12-01","Olaparib",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06833866","Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer","2026-06-01","Hydroxytyrosol",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,156,182,233,261,289,313,336,354,415,453,488,510,530,553,578,604,634,660,688,706,724,742,769,795,813,837,861,890,908,926,944,962,983,1009,1034,1052,1070,1088,1106,1124,1144,1165,1193,1211,1229,1253,1281,1302,1320,1346,1371,1397,1423,1447,1473,1498,1527,1545,1571,1596,1624,1650,1675,1747,1785,1811,1843,1875,1905,1927,1949,1975,1997,2022,2048,2072,2090,2108,2126,2148,2170,2188,2213,2231,2249,2267,2292,2310,2328,2346,2364,2389,2415,2440,2458,2476,2494,2520,2538,2556,2574,2592,2616,2644,2670,2697,2715,2740,2765,2790,2813,2841,2868,2886,2912,2937,2966,2984],{"intervention":95,"totalTrials":9,"cells":96},"Intraosseous Vancomycin",{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":120,"NA":144},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":119,"soonestReadout":111},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NCT06748144","IO Vancomycin Spine","NOT_YET_RECRUITING",[89,90],"2027-04","2030-04","2026-05",30,[116],"Lumbar Fusion Surgery",[95,118],"Intravenous Vancomycin",1,{"trials":121,"activeCount":119,"soonestReadout":111},[122,133],{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"NCT05705843","IO vs IV Vancomycin in Tourniquetless TKA","UNKNOWN",[91],"2024-01-25","2023-01-25",40,[131],"Infection, Surgical Site",[95,118],{"nctId":134,"briefTitle":135,"status":136,"phases":137,"primaryCompletion":111,"completion":138,"start":139,"enrollment":129,"conditions":140,"interventions":143},"NCT06384651","Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty","RECRUITING",[91],"2027-12","2024-12-03",[141,142],"Infections","Ankle Arthritis",[95,118],{"trials":145,"activeCount":119,"soonestReadout":150},[146],{"nctId":147,"briefTitle":148,"status":109,"phases":149,"primaryCompletion":150,"completion":151,"start":152,"enrollment":129,"conditions":153,"interventions":155},"NCT07283068","IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA",[92],"2030-02-15","2030-06-15","2026-06-15",[154],"Revision Total Knee Arthroplasty",[95],{"intervention":118,"totalTrials":34,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":170,"NA":180},{"trials":159,"activeCount":99},[],{"trials":161,"activeCount":99},[],{"trials":163,"activeCount":99},[],{"trials":165,"activeCount":119,"soonestReadout":111},[166],{"nctId":107,"briefTitle":108,"status":109,"phases":167,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":168,"interventions":169},[89,90],[116],[95,118],{"trials":171,"activeCount":119,"soonestReadout":111},[172,176],{"nctId":123,"briefTitle":124,"status":125,"phases":173,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":174,"interventions":175},[91],[131],[95,118],{"nctId":134,"briefTitle":135,"status":136,"phases":177,"primaryCompletion":111,"completion":138,"start":139,"enrollment":129,"conditions":178,"interventions":179},[91],[141,142],[95,118],{"trials":181,"activeCount":99},[],{"intervention":183,"totalTrials":34,"cells":184},"Bevacizumab",{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":215,"PHASE4":217,"NA":231},{"trials":186,"activeCount":99},[],{"trials":188,"activeCount":99},[],{"trials":190,"activeCount":119,"soonestReadout":206},[191,202],{"nctId":192,"briefTitle":193,"status":194,"phases":195,"primaryCompletion":196,"completion":197,"start":198,"enrollment":22,"conditions":199,"interventions":200},"NCT00440973","Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer","TERMINATED",[89],"2007-10","2007-11","2006-10",[21],[183,201],"Interleukin-2",{"nctId":203,"briefTitle":204,"status":136,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":12,"conditions":209,"interventions":211},"NCT06887218","5-Fluorouracil\u002FLeucovorin (5FU\u002FLV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer",[89],"2028-12","2029-12","2025-05-08",[210],"Metastatic Colorectal Cancer (CRC)",[212,213,183,214],"Regorafenib","5FU\u002FLV","Trifluridine-tipiracil",{"trials":216,"activeCount":99},[],{"trials":218,"activeCount":119,"soonestReadout":223},[219],{"nctId":220,"briefTitle":221,"status":136,"phases":222,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":230},"NCT05185505","Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria",[91],"2027-04-30","2027-10-31","2023-01-30",24,[228,229],"Hepatocellular Carcinoma","Hepatocellular Cancer",[70,183],{"trials":232,"activeCount":99},[],{"intervention":70,"totalTrials":234,"cells":235},2,{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":259},{"trials":237,"activeCount":99},[],{"trials":239,"activeCount":119,"soonestReadout":69},[240],{"nctId":67,"briefTitle":68,"status":241,"phases":242,"primaryCompletion":69,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":248},"ACTIVE_NOT_RECRUITING",[88],"2026-10-01","2020-09-25",20,[247],"Cutaneous Melanoma",[70],{"trials":250,"activeCount":99},[],{"trials":252,"activeCount":99},[],{"trials":254,"activeCount":119,"soonestReadout":223},[255],{"nctId":220,"briefTitle":221,"status":136,"phases":256,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":257,"interventions":258},[91],[228,229],[70,183],{"trials":260,"activeCount":99},[],{"intervention":262,"totalTrials":119,"cells":263},"Intraosseous Morphine",{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":287},{"trials":265,"activeCount":99},[],{"trials":267,"activeCount":99},[],{"trials":269,"activeCount":99},[],{"trials":271,"activeCount":99},[],{"trials":273,"activeCount":119,"soonestReadout":278},[274],{"nctId":275,"briefTitle":276,"status":136,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":286},"NCT06511232","Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction",[91],"2027-07-31","2029-07-31","2024-08-19",84,[283,284,285],"Anterior Cruciate Ligament Tear","Anterior Cruciate Ligament Injuries","Anterior Cruciate Ligament Rupture",[262],{"trials":288,"activeCount":99},[],{"intervention":60,"totalTrials":119,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":311},{"trials":292,"activeCount":99},[],{"trials":294,"activeCount":99},[],{"trials":296,"activeCount":99},[],{"trials":298,"activeCount":99},[],{"trials":300,"activeCount":119,"soonestReadout":59},[301],{"nctId":57,"briefTitle":58,"status":241,"phases":302,"primaryCompletion":59,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":310},[91],"2025-10-31","2018-09-01",46,[307,308,309],"Kidney Disease, End-Stage","Donor Specific Antibodies","Acute Rejection of Renal Transplant",[60],{"trials":312,"activeCount":99},[],{"intervention":50,"totalTrials":119,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":334},{"trials":316,"activeCount":99},[],{"trials":318,"activeCount":99},[],{"trials":320,"activeCount":99},[],{"trials":322,"activeCount":99},[],{"trials":324,"activeCount":119,"soonestReadout":49},[325],{"nctId":47,"briefTitle":48,"status":241,"phases":326,"primaryCompletion":49,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":332},[91],"2026-03-10","2023-06-01",33,[331],"Shoulder Injuries",[50,333],"Control - Standard IV administration of vancomycin",{"trials":335,"activeCount":99},[],{"intervention":333,"totalTrials":119,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":344,"PHASE4":346,"NA":352},{"trials":339,"activeCount":99},[],{"trials":341,"activeCount":99},[],{"trials":343,"activeCount":99},[],{"trials":345,"activeCount":99},[],{"trials":347,"activeCount":119,"soonestReadout":49},[348],{"nctId":47,"briefTitle":48,"status":241,"phases":349,"primaryCompletion":49,"completion":327,"start":328,"enrollment":329,"conditions":350,"interventions":351},[91],[331],[50,333],{"trials":353,"activeCount":99},[],{"intervention":355,"totalTrials":34,"cells":356},"L-NMMA",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":379,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":358,"activeCount":99},[],{"trials":360,"activeCount":99},[361],{"nctId":362,"briefTitle":363,"status":364,"phases":365,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":377},"NCT03236935","Phase Ib of L-NMMA and Pembrolizumab","COMPLETED",[88],"2021-10-31","2022-04-22","2018-08-27",12,[371,372,373,374,375,376],"Non-Small Cell Lung Cancer","Malignant Melanoma","Head and Neck Squamous Cell Carcinoma","Classical Hodgkin Lymphoma","Urothelial Carcinoma Bladder","DNA Repair-Deficiency Disorders",[355,378],"Pembrolizumab",{"trials":380,"activeCount":119,"soonestReadout":385},[381,395],{"nctId":382,"briefTitle":383,"status":136,"phases":384,"primaryCompletion":385,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":394},"NCT05660083","Alpelisib\u002FiNOS Inhibitor\u002FNab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)",[89],"2026-12-01","2028-12-02","2023-01-12",36,[390,391,392,393],"HER2-negative Breast Cancer","Metastatic Breast Cancer","Metaplastic Breast Carcinoma","TNBC - Triple-Negative Breast Cancer",[355],{"nctId":396,"briefTitle":397,"status":364,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":404},"NCT02834403","L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients",[88,89],"2021-01","2016-11",37,[403],"Metastatic Triple Negative Breast Cancer",[355,405,406,407,408],"Docetaxel","Amlodipine","Pegfilgrastim","Enteric-coated aspirin",{"trials":410,"activeCount":99},[],{"trials":412,"activeCount":99},[],{"trials":414,"activeCount":99},[],{"intervention":416,"totalTrials":234,"cells":417},"ADV\u002FHSV-tk",{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":419,"activeCount":99},[],{"trials":421,"activeCount":99},[],{"trials":423,"activeCount":119,"soonestReadout":440},[424,436],{"nctId":425,"briefTitle":426,"status":364,"phases":427,"primaryCompletion":428,"completion":429,"start":430,"enrollment":12,"conditions":431,"interventions":434},"NCT03004183","SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC",[89],"2022-07-22","2024-01-09","2017-07-01",[432,433],"Metastatic Non-small Cell Lung Cancer","Metastatic Triple-negative Breast Cancer",[416,435,378],"Valacyclovir",{"nctId":437,"briefTitle":438,"status":136,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":446},"NCT03603405","HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM",[88,89],"2026-12-31","2018-02-28",62,[444,445],"Glioblastoma","Anaplastic Astrocytoma",[416],{"trials":448,"activeCount":99},[],{"trials":450,"activeCount":99},[],{"trials":452,"activeCount":99},[],{"intervention":454,"totalTrials":234,"cells":455},"Trastuzumab",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":457,"activeCount":99},[],{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":119,"soonestReadout":54},[462,469],{"nctId":52,"briefTitle":53,"status":241,"phases":463,"primaryCompletion":54,"completion":206,"start":464,"enrollment":465,"conditions":466,"interventions":467},[89],"2020-06-30",51,[18],[55,454,468],"Pertuzumab",{"nctId":470,"briefTitle":471,"status":364,"phases":472,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":477},"NCT02073487","Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel",[89],"2019-01","2014-02",32,[18],[478,454,479,480,481,468],"T-DM1","Lapatinib","Abraxane","Paclitaxel",{"trials":483,"activeCount":99},[],{"trials":485,"activeCount":99},[],{"trials":487,"activeCount":99},[],{"intervention":468,"totalTrials":234,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":504,"PHASE4":506,"NA":508},{"trials":491,"activeCount":99},[],{"trials":493,"activeCount":99},[],{"trials":495,"activeCount":119,"soonestReadout":54},[496,500],{"nctId":52,"briefTitle":53,"status":241,"phases":497,"primaryCompletion":54,"completion":206,"start":464,"enrollment":465,"conditions":498,"interventions":499},[89],[18],[55,454,468],{"nctId":470,"briefTitle":471,"status":364,"phases":501,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":502,"interventions":503},[89],[18],[478,454,479,480,481,468],{"trials":505,"activeCount":99},[],{"trials":507,"activeCount":99},[],{"trials":509,"activeCount":99},[],{"intervention":40,"totalTrials":119,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":513,"activeCount":99},[],{"trials":515,"activeCount":99},[],{"trials":517,"activeCount":119,"soonestReadout":39},[518],{"nctId":37,"briefTitle":38,"status":136,"phases":519,"primaryCompletion":39,"completion":206,"start":520,"enrollment":521,"conditions":522,"interventions":523},[88,89],"2007-06",25,[15],[40],{"trials":525,"activeCount":99},[],{"trials":527,"activeCount":99},[],{"trials":529,"activeCount":99},[],{"intervention":531,"totalTrials":119,"cells":532},"Fruquintinib Combined With Chemotherapy",{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":547,"PHASE4":549,"NA":551},{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":99},[],{"trials":538,"activeCount":119,"soonestReadout":206},[539],{"nctId":540,"briefTitle":541,"status":136,"phases":542,"primaryCompletion":206,"completion":207,"start":543,"enrollment":544,"conditions":545,"interventions":546},"NCT07042685","Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer",[89],"2026-01-27",50,[210],[531],{"trials":548,"activeCount":99},[],{"trials":550,"activeCount":99},[],{"trials":552,"activeCount":99},[],{"intervention":554,"totalTrials":119,"cells":555},"Lenvatinib",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":99},[],{"trials":561,"activeCount":119,"soonestReadout":567},[562],{"nctId":563,"briefTitle":564,"status":565,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":544,"conditions":570,"interventions":571},"NCT05171335","Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients","ENROLLING_BY_INVITATION",[89],"2026-06-30","2027-12-30","2022-06-20",[228],[554],{"trials":573,"activeCount":99},[],{"trials":575,"activeCount":99},[],{"trials":577,"activeCount":99},[],{"intervention":579,"totalTrials":119,"cells":580},"Valganciclovir",{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":582,"activeCount":99},[],{"trials":584,"activeCount":99},[],{"trials":586,"activeCount":119,"soonestReadout":591},[587],{"nctId":588,"briefTitle":589,"status":136,"phases":590,"primaryCompletion":591,"completion":592,"start":113,"enrollment":593,"conditions":594,"interventions":597},"NCT07383649","Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection",[89],"2028-05","2030-05",28,[595,596],"Brain Cancer Metastatic","CMV Viremia",[579],{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":99},[],{"trials":603,"activeCount":99},[],{"intervention":605,"totalTrials":119,"cells":606},"Fingolimod",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":628,"PHASE4":630,"NA":632},{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":99},[],{"trials":612,"activeCount":119,"soonestReadout":617},[613],{"nctId":614,"briefTitle":615,"status":565,"phases":616,"primaryCompletion":617,"completion":138,"start":618,"enrollment":245,"conditions":619,"interventions":627},"NCT05285878","Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation",[89],"2027-06","2022-07-28",[620,621,622,623,624,625,626],"Interstitial Fibrosis","Kidney Transplant; Complications","Kidney Transplant Rejection","Kidney Transplant Failure and Rejection","Kidney Transplant Failure","Kidney Failure, Chronic","Graft Rejection",[605],{"trials":629,"activeCount":99},[],{"trials":631,"activeCount":99},[],{"trials":633,"activeCount":99},[],{"intervention":635,"totalTrials":119,"cells":636},"Epidiolex",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":638,"activeCount":99},[],{"trials":640,"activeCount":99},[],{"trials":642,"activeCount":119,"soonestReadout":647},[643],{"nctId":644,"briefTitle":645,"status":136,"phases":646,"primaryCompletion":647,"completion":568,"start":648,"enrollment":649,"conditions":650,"interventions":653},"NCT06381791","CBD for Pain Following Orthopedic Shoulder Surgery",[88,89],"2026-12-30","2024-05-24",80,[651,652],"Shoulder Osteoarthritis","Rotator Cuff Injuries",[635],{"trials":655,"activeCount":99},[],{"trials":657,"activeCount":99},[],{"trials":659,"activeCount":99},[],{"intervention":661,"totalTrials":119,"cells":662},"IO Administration of Cefazolin",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":664,"activeCount":99},[],{"trials":666,"activeCount":99},[],{"trials":668,"activeCount":119,"soonestReadout":673},[669],{"nctId":670,"briefTitle":671,"status":136,"phases":672,"primaryCompletion":673,"completion":674,"start":675,"enrollment":129,"conditions":676,"interventions":678},"NCT06640491","Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)",[88,89],"2030-12-01","2035-12-01","2025-05-15",[677],"Total Knee Arthroplasty",[661,679,680,681],"IO Administration of Vancomycin","IV Administration of Cefazolin","IV Administration of Vancomycin",{"trials":683,"activeCount":99},[],{"trials":685,"activeCount":99},[],{"trials":687,"activeCount":99},[],{"intervention":679,"totalTrials":119,"cells":689},{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":700,"PHASE4":702,"NA":704},{"trials":691,"activeCount":99},[],{"trials":693,"activeCount":99},[],{"trials":695,"activeCount":119,"soonestReadout":673},[696],{"nctId":670,"briefTitle":671,"status":136,"phases":697,"primaryCompletion":673,"completion":674,"start":675,"enrollment":129,"conditions":698,"interventions":699},[88,89],[677],[661,679,680,681],{"trials":701,"activeCount":99},[],{"trials":703,"activeCount":99},[],{"trials":705,"activeCount":99},[],{"intervention":680,"totalTrials":119,"cells":707},{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":709,"activeCount":99},[],{"trials":711,"activeCount":99},[],{"trials":713,"activeCount":119,"soonestReadout":673},[714],{"nctId":670,"briefTitle":671,"status":136,"phases":715,"primaryCompletion":673,"completion":674,"start":675,"enrollment":129,"conditions":716,"interventions":717},[88,89],[677],[661,679,680,681],{"trials":719,"activeCount":99},[],{"trials":721,"activeCount":99},[],{"trials":723,"activeCount":99},[],{"intervention":681,"totalTrials":119,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":727,"activeCount":99},[],{"trials":729,"activeCount":99},[],{"trials":731,"activeCount":119,"soonestReadout":673},[732],{"nctId":670,"briefTitle":671,"status":136,"phases":733,"primaryCompletion":673,"completion":674,"start":675,"enrollment":129,"conditions":734,"interventions":735},[88,89],[677],[661,679,680,681],{"trials":737,"activeCount":99},[],{"trials":739,"activeCount":99},[],{"trials":741,"activeCount":99},[],{"intervention":743,"totalTrials":119,"cells":744},"Venous ethanol",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":746,"activeCount":99},[],{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":119,"soonestReadout":755},[751],{"nctId":752,"briefTitle":753,"status":136,"phases":754,"primaryCompletion":755,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":762},"NCT05511246","Venous Ethanol for Ventricular Tachycardia",[89],"2027-12-12","2028-12-12","2023-04-12",156,[760,761],"Ventricular Tachycardia","Ischemic Cardiomyopathy",[743],{"trials":764,"activeCount":99},[],{"trials":766,"activeCount":99},[],{"trials":768,"activeCount":99},[],{"intervention":770,"totalTrials":119,"cells":771},"Dexamethasone Sodium Phosphate Injection 20 mg",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":789,"PHASE4":791,"NA":793},{"trials":773,"activeCount":99},[],{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":119,"soonestReadout":782},[778],{"nctId":779,"briefTitle":780,"status":136,"phases":781,"primaryCompletion":782,"completion":111,"start":783,"enrollment":784,"conditions":785,"interventions":787},"NCT06930690","Dexamethasone for Ureteral STent Symptoms (DUSTS)",[88,89],"2026-12","2026-06",70,[786],"Ureteral Stent-Related Symptom",[770,788],"Dexamethasone Sodium Phosphate Injection 4mg",{"trials":790,"activeCount":99},[],{"trials":792,"activeCount":99},[],{"trials":794,"activeCount":99},[],{"intervention":788,"totalTrials":119,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":798,"activeCount":99},[],{"trials":800,"activeCount":99},[],{"trials":802,"activeCount":119,"soonestReadout":782},[803],{"nctId":779,"briefTitle":780,"status":136,"phases":804,"primaryCompletion":782,"completion":111,"start":783,"enrollment":784,"conditions":805,"interventions":806},[88,89],[786],[770,788],{"trials":808,"activeCount":99},[],{"trials":810,"activeCount":99},[],{"trials":812,"activeCount":99},[],{"intervention":814,"totalTrials":119,"cells":815},"Brachytherapy",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":817,"activeCount":99},[],{"trials":819,"activeCount":99},[],{"trials":821,"activeCount":119,"soonestReadout":826},[822],{"nctId":823,"briefTitle":824,"status":136,"phases":825,"primaryCompletion":826,"completion":826,"start":64,"enrollment":827,"conditions":828,"interventions":830},"NCT07182279","Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer",[88,89],"2026-11-14",29,[829],"Prostate Cancer (Adenocarcinoma)",[814],{"trials":832,"activeCount":99},[],{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":99},[],{"intervention":838,"totalTrials":119,"cells":839},"Fulvestrant Run-In",{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":841,"activeCount":99},[],{"trials":843,"activeCount":99},[],{"trials":845,"activeCount":119,"soonestReadout":385},[846],{"nctId":847,"briefTitle":848,"status":136,"phases":849,"primaryCompletion":385,"completion":850,"start":851,"enrollment":593,"conditions":852,"interventions":854},"NCT05305924","Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer",[89],"2027-12-01","2021-02-25",[853,390],"ER-Positive Breast Cancer",[838],{"trials":856,"activeCount":99},[],{"trials":858,"activeCount":99},[],{"trials":860,"activeCount":99},[],{"intervention":862,"totalTrials":119,"cells":863},"Venetoclax",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":865,"activeCount":99},[],{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":119,"soonestReadout":206},[870],{"nctId":871,"briefTitle":872,"status":109,"phases":873,"primaryCompletion":206,"completion":207,"start":874,"enrollment":875,"conditions":876,"interventions":879},"NCT07060001","Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker",[89],"2026-04",112,[877,878],"Acute Myeloid Leukemia (AML)","Acute Myeloid Leukaemia (AML)",[862,880,881,882,883],"Decitabine 20 mg\u002Fm²\u002Fday for 5 days","Azacitidine","Cytarabine","Anthracycline",{"trials":885,"activeCount":99},[],{"trials":887,"activeCount":99},[],{"trials":889,"activeCount":99},[],{"intervention":880,"totalTrials":119,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":893,"activeCount":99},[],{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":119,"soonestReadout":206},[898],{"nctId":871,"briefTitle":872,"status":109,"phases":899,"primaryCompletion":206,"completion":207,"start":874,"enrollment":875,"conditions":900,"interventions":901},[89],[877,878],[862,880,881,882,883],{"trials":903,"activeCount":99},[],{"trials":905,"activeCount":99},[],{"trials":907,"activeCount":99},[],{"intervention":881,"totalTrials":119,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":119,"soonestReadout":206},[916],{"nctId":871,"briefTitle":872,"status":109,"phases":917,"primaryCompletion":206,"completion":207,"start":874,"enrollment":875,"conditions":918,"interventions":919},[89],[877,878],[862,880,881,882,883],{"trials":921,"activeCount":99},[],{"trials":923,"activeCount":99},[],{"trials":925,"activeCount":99},[],{"intervention":882,"totalTrials":119,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":929,"activeCount":99},[],{"trials":931,"activeCount":99},[],{"trials":933,"activeCount":119,"soonestReadout":206},[934],{"nctId":871,"briefTitle":872,"status":109,"phases":935,"primaryCompletion":206,"completion":207,"start":874,"enrollment":875,"conditions":936,"interventions":937},[89],[877,878],[862,880,881,882,883],{"trials":939,"activeCount":99},[],{"trials":941,"activeCount":99},[],{"trials":943,"activeCount":99},[],{"intervention":883,"totalTrials":119,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":947,"activeCount":99},[],{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":119,"soonestReadout":206},[952],{"nctId":871,"briefTitle":872,"status":109,"phases":953,"primaryCompletion":206,"completion":207,"start":874,"enrollment":875,"conditions":954,"interventions":955},[89],[877,878],[862,880,881,882,883],{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":99},[],{"trials":961,"activeCount":99},[],{"intervention":75,"totalTrials":119,"cells":963},{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":965,"activeCount":99},[],{"trials":967,"activeCount":99},[],{"trials":969,"activeCount":119,"soonestReadout":74},[970],{"nctId":72,"briefTitle":73,"status":241,"phases":971,"primaryCompletion":74,"completion":782,"start":972,"enrollment":226,"conditions":973,"interventions":976},[89],"2016-12",[974,975],"Renal Transplantation","Mesenchymal Stem Cells",[75],{"trials":978,"activeCount":99},[],{"trials":980,"activeCount":99},[],{"trials":982,"activeCount":99},[],{"intervention":984,"totalTrials":119,"cells":985},"Ocrelizumab",{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":987,"activeCount":99},[],{"trials":989,"activeCount":99},[],{"trials":991,"activeCount":119,"soonestReadout":996},[992],{"nctId":993,"briefTitle":994,"status":136,"phases":995,"primaryCompletion":996,"completion":997,"start":998,"enrollment":129,"conditions":999,"interventions":1002},"NCT03971487","Ocrelizumab for Psychosis by Autoimmunity",[88,89],"2028-06-30","2028-10-30","2019-10-01",[1000,1001],"Schizo-Affective Type of Psychosis","Schizophrenia",[984],{"trials":1004,"activeCount":99},[],{"trials":1006,"activeCount":99},[],{"trials":1008,"activeCount":99},[],{"intervention":1010,"totalTrials":119,"cells":1011},"Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1013,"activeCount":99},[],{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":119,"soonestReadout":1022},[1018],{"nctId":1019,"briefTitle":1020,"status":109,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":327,"enrollment":129,"conditions":1023,"interventions":1026},"NCT07048314","Stem Cells for Erectile Dysfunction Post RALP",[88,89],"2027-06-30",[1024,1025],"Erectile Dysfunction","Prostate Cancer",[1010,1027],"Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR",{"trials":1029,"activeCount":99},[],{"trials":1031,"activeCount":99},[],{"trials":1033,"activeCount":99},[],{"intervention":1027,"totalTrials":119,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":119,"soonestReadout":1022},[1042],{"nctId":1019,"briefTitle":1020,"status":109,"phases":1043,"primaryCompletion":1022,"completion":1022,"start":327,"enrollment":129,"conditions":1044,"interventions":1045},[88,89],[1024,1025],[1010,1027],{"trials":1047,"activeCount":99},[],{"trials":1049,"activeCount":99},[],{"trials":1051,"activeCount":99},[],{"intervention":212,"totalTrials":119,"cells":1053},{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1055,"activeCount":99},[],{"trials":1057,"activeCount":99},[],{"trials":1059,"activeCount":119,"soonestReadout":206},[1060],{"nctId":203,"briefTitle":204,"status":136,"phases":1061,"primaryCompletion":206,"completion":207,"start":208,"enrollment":12,"conditions":1062,"interventions":1063},[89],[210],[212,213,183,214],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[],{"trials":1069,"activeCount":99},[],{"intervention":213,"totalTrials":119,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1082,"PHASE4":1084,"NA":1086},{"trials":1073,"activeCount":99},[],{"trials":1075,"activeCount":99},[],{"trials":1077,"activeCount":119,"soonestReadout":206},[1078],{"nctId":203,"briefTitle":204,"status":136,"phases":1079,"primaryCompletion":206,"completion":207,"start":208,"enrollment":12,"conditions":1080,"interventions":1081},[89],[210],[212,213,183,214],{"trials":1083,"activeCount":99},[],{"trials":1085,"activeCount":99},[],{"trials":1087,"activeCount":99},[],{"intervention":214,"totalTrials":119,"cells":1089},{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1091,"activeCount":99},[],{"trials":1093,"activeCount":99},[],{"trials":1095,"activeCount":119,"soonestReadout":206},[1096],{"nctId":203,"briefTitle":204,"status":136,"phases":1097,"primaryCompletion":206,"completion":207,"start":208,"enrollment":12,"conditions":1098,"interventions":1099},[89],[210],[212,213,183,214],{"trials":1101,"activeCount":99},[],{"trials":1103,"activeCount":99},[],{"trials":1105,"activeCount":99},[],{"intervention":55,"totalTrials":119,"cells":1107},{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1118,"PHASE4":1120,"NA":1122},{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":99},[],{"trials":1113,"activeCount":119,"soonestReadout":54},[1114],{"nctId":52,"briefTitle":53,"status":241,"phases":1115,"primaryCompletion":54,"completion":206,"start":464,"enrollment":465,"conditions":1116,"interventions":1117},[89],[18],[55,454,468],{"trials":1119,"activeCount":99},[],{"trials":1121,"activeCount":99},[],{"trials":1123,"activeCount":99},[],{"intervention":65,"totalTrials":119,"cells":1125},{"EARLY_PHASE1":1126,"PHASE1":1128,"PHASE2":1130,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1127,"activeCount":99},[],{"trials":1129,"activeCount":99},[],{"trials":1131,"activeCount":119,"soonestReadout":64},[1132],{"nctId":62,"briefTitle":63,"status":241,"phases":1133,"primaryCompletion":64,"completion":1134,"start":1135,"enrollment":329,"conditions":1136,"interventions":1137},[89],"2027-04-01","2022-02-15",[375],[65],{"trials":1139,"activeCount":99},[],{"trials":1141,"activeCount":99},[],{"trials":1143,"activeCount":99},[],{"intervention":45,"totalTrials":119,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":119,"soonestReadout":44},[1152],{"nctId":42,"briefTitle":43,"status":241,"phases":1153,"primaryCompletion":44,"completion":1154,"start":1155,"enrollment":369,"conditions":1156,"interventions":1158},[89],"2022-08-31","2019-08-07",[1157],"ALS (Amyotrophic Lateral Sclerosis)",[45,45],{"trials":1160,"activeCount":99},[],{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[],{"intervention":1166,"totalTrials":119,"cells":1167},"All-Trans Retinoic Acid (ATRA) Dose 0",{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1169,"activeCount":99},[],{"trials":1171,"activeCount":99},[],{"trials":1173,"activeCount":119,"soonestReadout":1178},[1174],{"nctId":1175,"briefTitle":1176,"status":136,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1184},"NCT06536413","ATRA and Carfilzomib in Plasma Cell Myeloma Patients",[88,89],"2029-07","2030-07","2024-07-29",42,[1183],"Multiple Myeloma",[1166,1185,1186],"All-Trans Retinoic Acid (ATRA) Dose -1","All-Trans Retinoic Acid (ATRA) Dose 1",{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":99},[],{"trials":1192,"activeCount":99},[],{"intervention":1185,"totalTrials":119,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1196,"activeCount":99},[],{"trials":1198,"activeCount":99},[],{"trials":1200,"activeCount":119,"soonestReadout":1178},[1201],{"nctId":1175,"briefTitle":1176,"status":136,"phases":1202,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1203,"interventions":1204},[88,89],[1183],[1166,1185,1186],{"trials":1206,"activeCount":99},[],{"trials":1208,"activeCount":99},[],{"trials":1210,"activeCount":99},[],{"intervention":1186,"totalTrials":119,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1223,"PHASE4":1225,"NA":1227},{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[],{"trials":1218,"activeCount":119,"soonestReadout":1178},[1219],{"nctId":1175,"briefTitle":1176,"status":136,"phases":1220,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1221,"interventions":1222},[88,89],[1183],[1166,1185,1186],{"trials":1224,"activeCount":99},[],{"trials":1226,"activeCount":99},[],{"trials":1228,"activeCount":99},[],{"intervention":1230,"totalTrials":119,"cells":1231},"Belumosudil 200 mg QD",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1233,"activeCount":99},[],{"trials":1235,"activeCount":99},[],{"trials":1237,"activeCount":119,"soonestReadout":138},[1238],{"nctId":1239,"briefTitle":1240,"status":565,"phases":1241,"primaryCompletion":138,"completion":1242,"start":1243,"enrollment":129,"conditions":1244,"interventions":1246},"NCT06751602","Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation",[89],"2028-03-30","2025-09-11",[1245],"Rejection Chronic Renal",[1230],{"trials":1248,"activeCount":99},[],{"trials":1250,"activeCount":99},[],{"trials":1252,"activeCount":99},[],{"intervention":85,"totalTrials":234,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1265,"PHASE3":1267,"PHASE4":1277,"NA":1279},{"trials":1256,"activeCount":99},[],{"trials":1258,"activeCount":119,"soonestReadout":84},[1259],{"nctId":82,"briefTitle":83,"status":136,"phases":1260,"primaryCompletion":84,"completion":850,"start":1261,"enrollment":329,"conditions":1262,"interventions":1264},[88],"2024-12-04",[1263],"Advanced or Metastatic CRC",[85],{"trials":1266,"activeCount":99},[],{"trials":1268,"activeCount":99},[1269],{"nctId":1270,"briefTitle":1271,"status":364,"phases":1272,"primaryCompletion":1273,"completion":1273,"start":1274,"enrollment":465,"conditions":1275,"interventions":1276},"NCT02068092","Olive Oil for High Risk Breast Cancer Prevention in Women",[89,90],"2021-07","2013-12",[18],[85],{"trials":1278,"activeCount":99},[],{"trials":1280,"activeCount":99},[],{"intervention":80,"totalTrials":119,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1294,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1284,"activeCount":99},[],{"trials":1286,"activeCount":119,"soonestReadout":79},[1287],{"nctId":77,"briefTitle":78,"status":241,"phases":1288,"primaryCompletion":79,"completion":385,"start":1289,"enrollment":593,"conditions":1290,"interventions":1292},[88],"2019-06-11",[1291,18],"Breast Cancer Metastatic",[80,1293],"Vorinostat",{"trials":1295,"activeCount":99},[],{"trials":1297,"activeCount":99},[],{"trials":1299,"activeCount":99},[],{"trials":1301,"activeCount":99},[],{"intervention":1293,"totalTrials":119,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1312,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":119,"soonestReadout":79},[1308],{"nctId":77,"briefTitle":78,"status":241,"phases":1309,"primaryCompletion":79,"completion":385,"start":1289,"enrollment":593,"conditions":1310,"interventions":1311},[88],[1291,18],[80,1293],{"trials":1313,"activeCount":99},[],{"trials":1315,"activeCount":99},[],{"trials":1317,"activeCount":99},[],{"trials":1319,"activeCount":99},[],{"intervention":1321,"totalTrials":119,"cells":1322},"Autologous Mesenchymal Stromal Cells",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1324,"activeCount":99},[],{"trials":1326,"activeCount":119,"soonestReadout":1331},[1327],{"nctId":1328,"briefTitle":1329,"status":136,"phases":1330,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1337},"NCT06798623","Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells",[88],"2028-03","2030-03","2026-03-24",15,[1336],"Anterior Cruciate Ligament Reconstruction",[1321],{"trials":1339,"activeCount":99},[],{"trials":1341,"activeCount":99},[],{"trials":1343,"activeCount":99},[],{"trials":1345,"activeCount":99},[],{"intervention":1347,"totalTrials":119,"cells":1348},"Honokiol",{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1363,"PHASE3":1365,"PHASE4":1367,"NA":1369},{"trials":1350,"activeCount":99},[],{"trials":1352,"activeCount":119,"soonestReadout":1357},[1353],{"nctId":1354,"briefTitle":1355,"status":136,"phases":1356,"primaryCompletion":1357,"completion":1358,"start":1359,"enrollment":1334,"conditions":1360,"interventions":1362},"NCT06566443","Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer",[88],"2026-08","2027-08","2025-02-13",[1361],"Carcinoma, Non-Small-Cell Lung",[1347],{"trials":1364,"activeCount":99},[],{"trials":1366,"activeCount":99},[],{"trials":1368,"activeCount":99},[],{"trials":1370,"activeCount":99},[],{"intervention":1372,"totalTrials":119,"cells":1373},"Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg\u002Fm2 + 5-FU 2400 mg\u002Fm2 + LV 400 mg\u002Fm2 + oxaliplatin 60 mg\u002Fm2, IV) every 2 weeks for 12 months",{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1389,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1375,"activeCount":99},[],{"trials":1377,"activeCount":119,"soonestReadout":1382},[1378],{"nctId":1379,"briefTitle":1380,"status":109,"phases":1381,"primaryCompletion":1382,"completion":440,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1388},"NCT07060014","NALIRIFOX (Nal-IRI Plus 5-FU\u002FLV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers",[88],"2026-09-30","2025-07-18",22,[1386,1387],"Advanced Small Intestine Cancer","Appendiceal Cancers",[1372],{"trials":1390,"activeCount":99},[],{"trials":1392,"activeCount":99},[],{"trials":1394,"activeCount":99},[],{"trials":1396,"activeCount":99},[],{"intervention":1398,"totalTrials":119,"cells":1399},"Thymalfasin",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1415,"PHASE3":1417,"PHASE4":1419,"NA":1421},{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":119,"soonestReadout":385},[1404],{"nctId":1405,"briefTitle":1406,"status":136,"phases":1407,"primaryCompletion":385,"completion":385,"start":1408,"enrollment":1409,"conditions":1410,"interventions":1414},"NCT06821100","Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine",[88],"2024-12-02",75,[1411,1412,1413],"Vaccine Response","COVID-19 Vaccine","Immune Response to Covid 19 Vaccination",[1398],{"trials":1416,"activeCount":99},[],{"trials":1418,"activeCount":99},[],{"trials":1420,"activeCount":99},[],{"trials":1422,"activeCount":99},[],{"intervention":1424,"totalTrials":119,"cells":1425},"Positron Emission Tomography (PET) using 11C-ER176 for TSPO and 18F-SMBT1 for MAO-B",{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1427,"activeCount":99},[],{"trials":1429,"activeCount":99},[],{"trials":1431,"activeCount":99},[],{"trials":1433,"activeCount":99},[],{"trials":1435,"activeCount":99},[],{"trials":1437,"activeCount":119,"soonestReadout":224},[1438],{"nctId":1439,"briefTitle":1440,"status":136,"phases":1441,"primaryCompletion":224,"completion":1442,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1446},"NCT05582200","Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease",[],"2028-10-31","2023-01-20",71,[29,31],[1424],{"intervention":1448,"totalTrials":119,"cells":1449},"Corticosteroid",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1456,"PHASE4":1458,"NA":1471},{"trials":1451,"activeCount":99},[],{"trials":1453,"activeCount":99},[],{"trials":1455,"activeCount":99},[],{"trials":1457,"activeCount":99},[],{"trials":1459,"activeCount":99},[1460],{"nctId":1461,"briefTitle":1462,"status":194,"phases":1463,"primaryCompletion":1464,"completion":1465,"start":1466,"enrollment":475,"conditions":1467,"interventions":1470},"NCT00842933","Adrenal Insufficiency in Septic Shock",[91],"2010-05","2011-05","2007-05",[1468,1469],"Septic Shock","Acute Adrenal Insufficiency",[1448,1448],{"trials":1472,"activeCount":99},[],{"intervention":1474,"totalTrials":119,"cells":1475},"rATG",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1484,"NA":1496},{"trials":1477,"activeCount":99},[],{"trials":1479,"activeCount":99},[],{"trials":1481,"activeCount":99},[],{"trials":1483,"activeCount":99},[],{"trials":1485,"activeCount":99},[1486],{"nctId":1487,"briefTitle":1488,"status":125,"phases":1489,"primaryCompletion":1490,"completion":1491,"start":1492,"enrollment":114,"conditions":1493,"interventions":1495},"NCT02102854","Single Dose rATG for Renal Allograft Rejection",[91],"2021-03","2021-10","2014-03",[1494],"Acute (Cellular) Renal Allograft Rejection",[1474],{"trials":1497,"activeCount":99},[],{"intervention":1499,"totalTrials":119,"cells":1500},"Experimental Intraosseous vancomycin 500mg in 250 mL NS",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1507,"PHASE4":1509,"NA":1525},{"trials":1502,"activeCount":99},[],{"trials":1504,"activeCount":99},[],{"trials":1506,"activeCount":99},[],{"trials":1508,"activeCount":99},[],{"trials":1510,"activeCount":99},[1511],{"nctId":1512,"briefTitle":1513,"status":364,"phases":1514,"primaryCompletion":1515,"completion":1516,"start":1517,"enrollment":1518,"conditions":1519,"interventions":1523},"NCT04042233","Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol",[91],"2022-05-25","2022-09-01","2019-12-31",23,[1520,1521,1522],"Prosthetic Joint Infection","Vancomycin","Joint Diseases",[1499,1524],"Standard IV administration of vancomycin",{"trials":1526,"activeCount":99},[],{"intervention":1524,"totalTrials":119,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1543},{"trials":1530,"activeCount":99},[],{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[],{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[1539],{"nctId":1512,"briefTitle":1513,"status":364,"phases":1540,"primaryCompletion":1515,"completion":1516,"start":1517,"enrollment":1518,"conditions":1541,"interventions":1542},[91],[1520,1521,1522],[1499,1524],{"trials":1544,"activeCount":99},[],{"intervention":1546,"totalTrials":119,"cells":1547},"Ciprofloxacin",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1569},{"trials":1549,"activeCount":99},[],{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[],{"trials":1557,"activeCount":99},[1558],{"nctId":1559,"briefTitle":1560,"status":364,"phases":1561,"primaryCompletion":1562,"completion":1563,"start":1564,"enrollment":1565,"conditions":1566,"interventions":1568},"NCT01789203","Ciprofloxacin for Prevention of BK Infection",[91],"2017-04","2017-10","2013-01",200,[1567],"BK Virus Infection",[1546],{"trials":1570,"activeCount":99},[],{"intervention":1572,"totalTrials":119,"cells":1573},"Intradetrusor Botox Injections",{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1582,"NA":1594},{"trials":1575,"activeCount":99},[],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[],{"trials":1583,"activeCount":99},[1584],{"nctId":1585,"briefTitle":1586,"status":364,"phases":1587,"primaryCompletion":1588,"completion":1589,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1593},"NCT05652036","Procedural Discomfort Related to Number of Intradetrusor Botox Injections",[91],"2023-04-06","2023-05-15","2022-07-07",108,[27],[1572],{"trials":1595,"activeCount":99},[],{"intervention":1597,"totalTrials":119,"cells":1598},"Morphine",{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1603,"PHASE3":1605,"PHASE4":1607,"NA":1622},{"trials":1600,"activeCount":99},[],{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":99},[],{"trials":1606,"activeCount":99},[],{"trials":1608,"activeCount":99},[1609],{"nctId":1610,"briefTitle":1611,"status":364,"phases":1612,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":1616,"conditions":1617,"interventions":1621},"NCT04388111","Intraosseous Morphine in Primary TKA",[91],"2021-04-30","2021-05-31","2020-05-05",65,[1618,1619,1620],"Knee Disease","Arthritis Knee","Pain, Acute",[1597],{"trials":1623,"activeCount":99},[],{"intervention":1625,"totalTrials":119,"cells":1626},"Low-Dose Lidocaine",{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1631,"PHASE3":1633,"PHASE4":1635,"NA":1648},{"trials":1628,"activeCount":99},[],{"trials":1630,"activeCount":99},[],{"trials":1632,"activeCount":99},[],{"trials":1634,"activeCount":99},[],{"trials":1636,"activeCount":99},[1637],{"nctId":1638,"briefTitle":1639,"status":364,"phases":1640,"primaryCompletion":1641,"completion":1642,"start":1643,"enrollment":1644,"conditions":1645,"interventions":1647},"NCT06725485","Low-Dose Lidocaine Infusion for Acute Pain Management Pilot Study",[91],"2024-02-16","2024-06-17","2021-07-02",18,[1646],"Postoperative Pain Management",[1625],{"trials":1649,"activeCount":99},[],{"intervention":1651,"totalTrials":119,"cells":1652},"Ethanol",{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1657,"PHASE3":1659,"PHASE4":1671,"NA":1673},{"trials":1654,"activeCount":99},[],{"trials":1656,"activeCount":99},[],{"trials":1658,"activeCount":99},[],{"trials":1660,"activeCount":99},[1661],{"nctId":1662,"briefTitle":1663,"status":364,"phases":1664,"primaryCompletion":1665,"completion":1665,"start":1666,"enrollment":1667,"conditions":1668,"interventions":1670},"NCT01898221","Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation",[90],"2019-12","2013-10",343,[760,1669],"Atrial Fibrillation",[1651],{"trials":1672,"activeCount":99},[],{"trials":1674,"activeCount":99},[],{"intervention":405,"totalTrials":22,"cells":1676},{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1741,"PHASE4":1743,"NA":1745},{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[],{"trials":1682,"activeCount":99},[1683,1694,1705,1715,1726,1737],{"nctId":1684,"briefTitle":1685,"status":364,"phases":1686,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1689,"conditions":1690,"interventions":1692},"NCT01446016","Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)",[89],"2019-03-01","2011-09",38,[1691,18],"Breast Neoplasms",[481,405,480,1693],"Ixabepilone",{"nctId":1695,"briefTitle":1696,"status":194,"phases":1697,"primaryCompletion":1698,"completion":1699,"start":1700,"enrollment":1701,"conditions":1702,"interventions":1703},"NCT00521274","Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer",[89],"2008-07","2008-08","2007-08",11,[15],[1704,405],"MVA 5T4",{"nctId":1706,"briefTitle":1707,"status":194,"phases":1708,"primaryCompletion":1709,"completion":1699,"start":1710,"enrollment":19,"conditions":1711,"interventions":1712},"NCT00448097","Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy",[89],"2008-06","2007-02",[15],[1713,1714],"cetuximab","docetaxel",{"nctId":1716,"briefTitle":1717,"status":194,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":16,"conditions":1721,"interventions":1724},"NCT04095689","Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer",[89],"2024-06-03","2021-05-12",[1722,1723],"Triple Negative Breast Cancer","Anthracycline-refractory TNBC",[405,378,1725],"IL-12 gene therapy",{"nctId":1727,"briefTitle":1728,"status":194,"phases":1729,"primaryCompletion":1699,"completion":1730,"start":1731,"enrollment":1732,"conditions":1733,"interventions":1734},"NCT00450008","Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer",[89],"2008-09","2006-12",9,[15],[1735,1736,1714],"GM-CSF","thalidomide",{"nctId":396,"briefTitle":397,"status":364,"phases":1738,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":1739,"interventions":1740},[88,89],[403],[355,405,406,407,408],{"trials":1742,"activeCount":99},[],{"trials":1744,"activeCount":99},[],{"trials":1746,"activeCount":99},[],{"intervention":1735,"totalTrials":34,"cells":1748},{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1779,"PHASE4":1781,"NA":1783},{"trials":1750,"activeCount":99},[],{"trials":1752,"activeCount":99},[],{"trials":1754,"activeCount":99},[1755,1765,1769],{"nctId":1756,"briefTitle":1757,"status":194,"phases":1758,"primaryCompletion":1699,"completion":1730,"start":1759,"enrollment":1760,"conditions":1761,"interventions":1762},"NCT00447473","Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer",[89],"2006-07",31,[15],[1735,1763,1764],"Ketoconazole","Mitoxantrone",{"nctId":1727,"briefTitle":1728,"status":194,"phases":1766,"primaryCompletion":1699,"completion":1730,"start":1731,"enrollment":1732,"conditions":1767,"interventions":1768},[89],[15],[1735,1736,1714],{"nctId":1770,"briefTitle":1771,"status":364,"phases":1772,"primaryCompletion":1773,"completion":1466,"start":1774,"enrollment":1775,"conditions":1776,"interventions":1777},"NCT00448409","Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer",[89],"2007-04","2006-05",27,[15],[1778,1735],"TroVax",{"trials":1780,"activeCount":99},[],{"trials":1782,"activeCount":99},[],{"trials":1784,"activeCount":99},[],{"intervention":378,"totalTrials":34,"cells":1786},{"EARLY_PHASE1":1787,"PHASE1":1789,"PHASE2":1795,"PHASE3":1805,"PHASE4":1807,"NA":1809},{"trials":1788,"activeCount":99},[],{"trials":1790,"activeCount":99},[1791],{"nctId":362,"briefTitle":363,"status":364,"phases":1792,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":1793,"interventions":1794},[88],[371,372,373,374,375,376],[355,378],{"trials":1796,"activeCount":99},[1797,1801],{"nctId":425,"briefTitle":426,"status":364,"phases":1798,"primaryCompletion":428,"completion":429,"start":430,"enrollment":12,"conditions":1799,"interventions":1800},[89],[432,433],[416,435,378],{"nctId":1716,"briefTitle":1717,"status":194,"phases":1802,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":16,"conditions":1803,"interventions":1804},[89],[1722,1723],[405,378,1725],{"trials":1806,"activeCount":99},[],{"trials":1808,"activeCount":99},[],{"trials":1810,"activeCount":99},[],{"intervention":480,"totalTrials":34,"cells":1812},{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1814,"activeCount":99},[],{"trials":1816,"activeCount":99},[],{"trials":1818,"activeCount":99},[1819,1829,1833],{"nctId":1820,"briefTitle":1821,"status":194,"phases":1822,"primaryCompletion":1730,"completion":1823,"start":1700,"enrollment":1824,"conditions":1825,"interventions":1826},"NCT00521781","Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer",[89],"2008-10",14,[15],[480,1827,1828],"Leuprolide","Bicalutamide",{"nctId":1684,"briefTitle":1685,"status":364,"phases":1830,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1689,"conditions":1831,"interventions":1832},[89],[1691,18],[481,405,480,1693],{"nctId":470,"briefTitle":471,"status":364,"phases":1834,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":1835,"interventions":1836},[89],[18],[478,454,479,480,481,468],{"trials":1838,"activeCount":99},[],{"trials":1840,"activeCount":99},[],{"trials":1842,"activeCount":99},[],{"intervention":1844,"totalTrials":234,"cells":1845},"RAD001",{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1869,"PHASE4":1871,"NA":1873},{"trials":1847,"activeCount":99},[],{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":99},[1852,1860],{"nctId":1853,"briefTitle":1854,"status":364,"phases":1855,"primaryCompletion":1730,"completion":1823,"start":1856,"enrollment":1857,"conditions":1858,"interventions":1859},"NCT00446368","Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer",[89],"2005-05",66,[21],[1844],{"nctId":1861,"briefTitle":1862,"status":364,"phases":1863,"primaryCompletion":1864,"completion":1864,"start":1731,"enrollment":1865,"conditions":1866,"interventions":1867},"NCT00448149","Phase I\u002FII Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer",[88,89],"2009-06",55,[21],[1844,1868],"Sorafenib",{"trials":1870,"activeCount":99},[],{"trials":1872,"activeCount":99},[],{"trials":1874,"activeCount":99},[],{"intervention":435,"totalTrials":234,"cells":1876},{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1899,"PHASE4":1901,"NA":1903},{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[1883,1887],{"nctId":425,"briefTitle":426,"status":364,"phases":1884,"primaryCompletion":428,"completion":429,"start":430,"enrollment":12,"conditions":1885,"interventions":1886},[89],[432,433],[416,435,378],{"nctId":1888,"briefTitle":1889,"status":125,"phases":1890,"primaryCompletion":1891,"completion":1891,"start":1892,"enrollment":1893,"conditions":1894,"interventions":1896},"NCT03541928","Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery",[89],"2023-07","2018-08-02",60,[1895,1025],"High-risk Prostate Cancer",[1897,435,1828,1898],"HSV-Tk","Leuprolide Acetate",{"trials":1900,"activeCount":99},[],{"trials":1902,"activeCount":99},[],{"trials":1904,"activeCount":99},[],{"intervention":1828,"totalTrials":234,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1908,"activeCount":99},[],{"trials":1910,"activeCount":99},[],{"trials":1912,"activeCount":99},[1913,1917],{"nctId":1820,"briefTitle":1821,"status":194,"phases":1914,"primaryCompletion":1730,"completion":1823,"start":1700,"enrollment":1824,"conditions":1915,"interventions":1916},[89],[15],[480,1827,1828],{"nctId":1888,"briefTitle":1889,"status":125,"phases":1918,"primaryCompletion":1891,"completion":1891,"start":1892,"enrollment":1893,"conditions":1919,"interventions":1920},[89],[1895,1025],[1897,435,1828,1898],{"trials":1922,"activeCount":99},[],{"trials":1924,"activeCount":99},[],{"trials":1926,"activeCount":99},[],{"intervention":481,"totalTrials":234,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1943,"PHASE4":1945,"NA":1947},{"trials":1930,"activeCount":99},[],{"trials":1932,"activeCount":99},[],{"trials":1934,"activeCount":99},[1935,1939],{"nctId":1684,"briefTitle":1685,"status":364,"phases":1936,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1689,"conditions":1937,"interventions":1938},[89],[1691,18],[481,405,480,1693],{"nctId":470,"briefTitle":471,"status":364,"phases":1940,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":1941,"interventions":1942},[89],[18],[478,454,479,480,481,468],{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[],{"trials":1948,"activeCount":99},[],{"intervention":1693,"totalTrials":234,"cells":1950},{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1969,"PHASE4":1971,"NA":1973},{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[],{"trials":1956,"activeCount":99},[1957,1961],{"nctId":1684,"briefTitle":1685,"status":364,"phases":1958,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1689,"conditions":1959,"interventions":1960},[89],[1691,18],[481,405,480,1693],{"nctId":1962,"briefTitle":1963,"status":364,"phases":1964,"primaryCompletion":1665,"completion":1665,"start":1965,"enrollment":129,"conditions":1966,"interventions":1967},"NCT01097642","Neo-Adjuvant Study in Triple Negative Breast Cancer Patients",[89],"2008-10-10",[18],[1968,1693],"Cetuximab",{"trials":1970,"activeCount":99},[],{"trials":1972,"activeCount":99},[],{"trials":1974,"activeCount":99},[],{"intervention":1713,"totalTrials":234,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1991,"PHASE4":1993,"NA":1995},{"trials":1978,"activeCount":99},[],{"trials":1980,"activeCount":99},[],{"trials":1982,"activeCount":99},[1983,1987],{"nctId":1706,"briefTitle":1707,"status":194,"phases":1984,"primaryCompletion":1709,"completion":1699,"start":1710,"enrollment":19,"conditions":1985,"interventions":1986},[89],[15],[1713,1714],{"nctId":1962,"briefTitle":1963,"status":364,"phases":1988,"primaryCompletion":1665,"completion":1665,"start":1965,"enrollment":129,"conditions":1989,"interventions":1990},[89],[18],[1968,1693],{"trials":1992,"activeCount":99},[],{"trials":1994,"activeCount":99},[],{"trials":1996,"activeCount":99},[],{"intervention":1868,"totalTrials":234,"cells":1998},{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2003,"PHASE3":2016,"PHASE4":2018,"NA":2020},{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[2005,2012],{"nctId":2006,"briefTitle":2007,"status":364,"phases":2008,"primaryCompletion":1730,"completion":1823,"start":2009,"enrollment":1444,"conditions":2010,"interventions":2011},"NCT00445042","Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer",[89],"2005-11",[21],[1868],{"nctId":1861,"briefTitle":1862,"status":364,"phases":2013,"primaryCompletion":1864,"completion":1864,"start":1731,"enrollment":1865,"conditions":2014,"interventions":2015},[88,89],[21],[1844,1868],{"trials":2017,"activeCount":99},[],{"trials":2019,"activeCount":99},[],{"trials":2021,"activeCount":99},[],{"intervention":201,"totalTrials":234,"cells":2023},{"EARLY_PHASE1":2024,"PHASE1":2026,"PHASE2":2028,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2025,"activeCount":99},[],{"trials":2027,"activeCount":99},[],{"trials":2029,"activeCount":99},[2030,2034],{"nctId":192,"briefTitle":193,"status":194,"phases":2031,"primaryCompletion":196,"completion":197,"start":198,"enrollment":22,"conditions":2032,"interventions":2033},[89],[21],[183,201],{"nctId":2035,"briefTitle":2036,"status":125,"phases":2037,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":129,"conditions":2040,"interventions":2041},"NCT06096090","Phase II Clinical Trial of Interleukin-2 in AD",[89],"2025-12-30","2022-01-01",[29],[201],{"trials":2043,"activeCount":99},[],{"trials":2045,"activeCount":99},[],{"trials":2047,"activeCount":99},[],{"intervention":2049,"totalTrials":119,"cells":2050},"TroVax®",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2052,"activeCount":99},[],{"trials":2054,"activeCount":99},[],{"trials":2056,"activeCount":99},[2057],{"nctId":2058,"briefTitle":2059,"status":364,"phases":2060,"primaryCompletion":2061,"completion":2062,"start":1774,"enrollment":593,"conditions":2063,"interventions":2064},"NCT00445523","Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer",[89],"2008-01","2008-02",[21],[2049,2065],"Interferon-alpha",{"trials":2067,"activeCount":99},[],{"trials":2069,"activeCount":99},[],{"trials":2071,"activeCount":99},[],{"intervention":2065,"totalTrials":119,"cells":2073},{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[],{"trials":2079,"activeCount":99},[2080],{"nctId":2058,"briefTitle":2059,"status":364,"phases":2081,"primaryCompletion":2061,"completion":2062,"start":1774,"enrollment":593,"conditions":2082,"interventions":2083},[89],[21],[2049,2065],{"trials":2085,"activeCount":99},[],{"trials":2087,"activeCount":99},[],{"trials":2089,"activeCount":99},[],{"intervention":1763,"totalTrials":119,"cells":2091},{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2096,"PHASE3":2102,"PHASE4":2104,"NA":2106},{"trials":2093,"activeCount":99},[],{"trials":2095,"activeCount":99},[],{"trials":2097,"activeCount":99},[2098],{"nctId":1756,"briefTitle":1757,"status":194,"phases":2099,"primaryCompletion":1699,"completion":1730,"start":1759,"enrollment":1760,"conditions":2100,"interventions":2101},[89],[15],[1735,1763,1764],{"trials":2103,"activeCount":99},[],{"trials":2105,"activeCount":99},[],{"trials":2107,"activeCount":99},[],{"intervention":1764,"totalTrials":119,"cells":2109},{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2120,"PHASE4":2122,"NA":2124},{"trials":2111,"activeCount":99},[],{"trials":2113,"activeCount":99},[],{"trials":2115,"activeCount":99},[2116],{"nctId":1756,"briefTitle":1757,"status":194,"phases":2117,"primaryCompletion":1699,"completion":1730,"start":1759,"enrollment":1760,"conditions":2118,"interventions":2119},[89],[15],[1735,1763,1764],{"trials":2121,"activeCount":99},[],{"trials":2123,"activeCount":99},[],{"trials":2125,"activeCount":99},[],{"intervention":2127,"totalTrials":119,"cells":2128},"Paclitaxel polyglumex",{"EARLY_PHASE1":2129,"PHASE1":2131,"PHASE2":2133,"PHASE3":2142,"PHASE4":2144,"NA":2146},{"trials":2130,"activeCount":99},[],{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[2135],{"nctId":2136,"briefTitle":2137,"status":364,"phases":2138,"primaryCompletion":197,"completion":2061,"start":2139,"enrollment":827,"conditions":2140,"interventions":2141},"NCT00446836","Efficacy and Safety Study of Xyotax to Treat Prostate Cancer",[89],"2005-03",[15],[2127],{"trials":2143,"activeCount":99},[],{"trials":2145,"activeCount":99},[],{"trials":2147,"activeCount":99},[],{"intervention":2149,"totalTrials":119,"cells":2150},"11C-ER176",{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[],{"trials":2156,"activeCount":99},[2157],{"nctId":2158,"briefTitle":2159,"status":125,"phases":2160,"primaryCompletion":2038,"completion":2038,"start":2161,"enrollment":129,"conditions":2162,"interventions":2163},"NCT06384378","Systemic and Central Inflammation in AD",[89],"2023-03-17",[29],[2149],{"trials":2165,"activeCount":99},[],{"trials":2167,"activeCount":99},[],{"trials":2169,"activeCount":99},[],{"intervention":1827,"totalTrials":119,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2173,"activeCount":99},[],{"trials":2175,"activeCount":99},[],{"trials":2177,"activeCount":99},[2178],{"nctId":1820,"briefTitle":1821,"status":194,"phases":2179,"primaryCompletion":1730,"completion":1823,"start":1700,"enrollment":1824,"conditions":2180,"interventions":2181},[89],[15],[480,1827,1828],{"trials":2183,"activeCount":99},[],{"trials":2185,"activeCount":99},[],{"trials":2187,"activeCount":99},[],{"intervention":2189,"totalTrials":119,"cells":2190},"Pegylated Alfa Interferon",{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2195,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2192,"activeCount":99},[],{"trials":2194,"activeCount":99},[],{"trials":2196,"activeCount":99},[2197],{"nctId":2198,"briefTitle":2199,"status":194,"phases":2200,"primaryCompletion":2201,"completion":1698,"start":1466,"enrollment":2202,"conditions":2203,"interventions":2204},"NCT00522249","Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC",[88,89],"2008-05",10,[21],[2189,2205,2206],"sunitinib","erlotinib",{"trials":2208,"activeCount":99},[],{"trials":2210,"activeCount":99},[],{"trials":2212,"activeCount":99},[],{"intervention":2205,"totalTrials":119,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":99},[],{"trials":2218,"activeCount":99},[],{"trials":2220,"activeCount":99},[2221],{"nctId":2198,"briefTitle":2199,"status":194,"phases":2222,"primaryCompletion":2201,"completion":1698,"start":1466,"enrollment":2202,"conditions":2223,"interventions":2224},[88,89],[21],[2189,2205,2206],{"trials":2226,"activeCount":99},[],{"trials":2228,"activeCount":99},[],{"trials":2230,"activeCount":99},[],{"intervention":2206,"totalTrials":119,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2243,"PHASE4":2245,"NA":2247},{"trials":2234,"activeCount":99},[],{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[2239],{"nctId":2198,"briefTitle":2199,"status":194,"phases":2240,"primaryCompletion":2201,"completion":1698,"start":1466,"enrollment":2202,"conditions":2241,"interventions":2242},[88,89],[21],[2189,2205,2206],{"trials":2244,"activeCount":99},[],{"trials":2246,"activeCount":99},[],{"trials":2248,"activeCount":99},[],{"intervention":1704,"totalTrials":119,"cells":2250},{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2255,"PHASE3":2261,"PHASE4":2263,"NA":2265},{"trials":2252,"activeCount":99},[],{"trials":2254,"activeCount":99},[],{"trials":2256,"activeCount":99},[2257],{"nctId":1695,"briefTitle":1696,"status":194,"phases":2258,"primaryCompletion":1698,"completion":1699,"start":1700,"enrollment":1701,"conditions":2259,"interventions":2260},[89],[15],[1704,405],{"trials":2262,"activeCount":99},[],{"trials":2264,"activeCount":99},[],{"trials":2266,"activeCount":99},[],{"intervention":2268,"totalTrials":119,"cells":2269},"Clazakizumab",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2286,"PHASE4":2288,"NA":2290},{"trials":2271,"activeCount":99},[],{"trials":2273,"activeCount":99},[],{"trials":2275,"activeCount":99},[2276],{"nctId":2277,"briefTitle":2278,"status":125,"phases":2279,"primaryCompletion":2280,"completion":2281,"start":2282,"enrollment":1893,"conditions":2283,"interventions":2285},"NCT04494724","Clazakizumab vs. Placebo - COVID-19 Infection",[89],"2020-12-31","2021-07-31","2020-07-13",[2284],"COVID-19 Infection",[2268],{"trials":2287,"activeCount":99},[],{"trials":2289,"activeCount":99},[],{"trials":2291,"activeCount":99},[],{"intervention":1725,"totalTrials":119,"cells":2293},{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2298,"PHASE3":2304,"PHASE4":2306,"NA":2308},{"trials":2295,"activeCount":99},[],{"trials":2297,"activeCount":99},[],{"trials":2299,"activeCount":99},[2300],{"nctId":1716,"briefTitle":1717,"status":194,"phases":2301,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":16,"conditions":2302,"interventions":2303},[89],[1722,1723],[405,378,1725],{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[],{"intervention":1736,"totalTrials":119,"cells":2311},{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2322,"PHASE4":2324,"NA":2326},{"trials":2313,"activeCount":99},[],{"trials":2315,"activeCount":99},[],{"trials":2317,"activeCount":99},[2318],{"nctId":1727,"briefTitle":1728,"status":194,"phases":2319,"primaryCompletion":1699,"completion":1730,"start":1731,"enrollment":1732,"conditions":2320,"interventions":2321},[89],[15],[1735,1736,1714],{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"intervention":1897,"totalTrials":119,"cells":2329},{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2334,"PHASE3":2340,"PHASE4":2342,"NA":2344},{"trials":2331,"activeCount":99},[],{"trials":2333,"activeCount":99},[],{"trials":2335,"activeCount":99},[2336],{"nctId":1888,"briefTitle":1889,"status":125,"phases":2337,"primaryCompletion":1891,"completion":1891,"start":1892,"enrollment":1893,"conditions":2338,"interventions":2339},[89],[1895,1025],[1897,435,1828,1898],{"trials":2341,"activeCount":99},[],{"trials":2343,"activeCount":99},[],{"trials":2345,"activeCount":99},[],{"intervention":1898,"totalTrials":119,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2358,"PHASE4":2360,"NA":2362},{"trials":2349,"activeCount":99},[],{"trials":2351,"activeCount":99},[],{"trials":2353,"activeCount":99},[2354],{"nctId":1888,"briefTitle":1889,"status":125,"phases":2355,"primaryCompletion":1891,"completion":1891,"start":1892,"enrollment":1893,"conditions":2356,"interventions":2357},[89],[1895,1025],[1897,435,1828,1898],{"trials":2359,"activeCount":99},[],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[],{"intervention":2365,"totalTrials":119,"cells":2366},"Vorinostat in combination with Bortezomib",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2383,"PHASE4":2385,"NA":2387},{"trials":2368,"activeCount":99},[],{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[2373],{"nctId":2374,"briefTitle":2375,"status":2376,"phases":2377,"primaryCompletion":2378,"completion":2378,"start":2379,"enrollment":99,"conditions":2380,"interventions":2382},"NCT00837174","Relapsed and\u002For Refractory Non-Hodgkin Lymphoma Study","WITHDRAWN",[89],"2012-05","2010-06",[2381],"Non-Hodgkin Lymphoma",[2365],{"trials":2384,"activeCount":99},[],{"trials":2386,"activeCount":99},[],{"trials":2388,"activeCount":99},[],{"intervention":2390,"totalTrials":119,"cells":2391},"Topotecan",{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2396,"PHASE3":2409,"PHASE4":2411,"NA":2413},{"trials":2393,"activeCount":99},[],{"trials":2395,"activeCount":99},[],{"trials":2397,"activeCount":99},[2398],{"nctId":2399,"briefTitle":2400,"status":2376,"phases":2401,"primaryCompletion":2402,"completion":2402,"start":2403,"enrollment":99,"conditions":2404,"interventions":2407},"NCT01736800","Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors",[89],"2014-11","2007-03",[2405,2406],"Central Nervous System (CNS) Metastases","Brain Metastases",[2390,2408],"Temozolomide",{"trials":2410,"activeCount":99},[],{"trials":2412,"activeCount":99},[],{"trials":2414,"activeCount":99},[],{"intervention":2416,"totalTrials":119,"cells":2417},"68Ga-PSMA",{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[],{"trials":2423,"activeCount":99},[2424],{"nctId":2425,"briefTitle":2426,"status":364,"phases":2427,"primaryCompletion":2428,"completion":2429,"start":2430,"enrollment":649,"conditions":2431,"interventions":2433},"NCT04614363","68 Ga-PSMA for High Risk Prostate Cancer",[88,89],"2022-02-26","2023-04-25","2020-10-13",[1025,2432],"High Risk",[2416],{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[],{"trials":2439,"activeCount":99},[],{"intervention":406,"totalTrials":119,"cells":2441},{"EARLY_PHASE1":2442,"PHASE1":2444,"PHASE2":2446,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2443,"activeCount":99},[],{"trials":2445,"activeCount":99},[],{"trials":2447,"activeCount":99},[2448],{"nctId":396,"briefTitle":397,"status":364,"phases":2449,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":2450,"interventions":2451},[88,89],[403],[355,405,406,407,408],{"trials":2453,"activeCount":99},[],{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[],{"intervention":407,"totalTrials":119,"cells":2459},{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"trials":2465,"activeCount":99},[2466],{"nctId":396,"briefTitle":397,"status":364,"phases":2467,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":2468,"interventions":2469},[88,89],[403],[355,405,406,407,408],{"trials":2471,"activeCount":99},[],{"trials":2473,"activeCount":99},[],{"trials":2475,"activeCount":99},[],{"intervention":408,"totalTrials":119,"cells":2477},{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2482,"PHASE3":2488,"PHASE4":2490,"NA":2492},{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[],{"trials":2483,"activeCount":99},[2484],{"nctId":396,"briefTitle":397,"status":364,"phases":2485,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":2486,"interventions":2487},[88,89],[403],[355,405,406,407,408],{"trials":2489,"activeCount":99},[],{"trials":2491,"activeCount":99},[],{"trials":2493,"activeCount":99},[],{"intervention":2495,"totalTrials":119,"cells":2496},"TAK-228",{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2514,"PHASE4":2516,"NA":2518},{"trials":2498,"activeCount":99},[],{"trials":2500,"activeCount":99},[],{"trials":2502,"activeCount":99},[2503],{"nctId":2504,"briefTitle":2505,"status":364,"phases":2506,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":593,"conditions":2510,"interventions":2512},"NCT02988986","TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",[89],"2019-02-01","2019-03-30","2017-04-24",[2511],"Estrogen Receptor Positive Breast Cancer",[2495,2513],"Tamoxifen",{"trials":2515,"activeCount":99},[],{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[],{"intervention":2513,"totalTrials":119,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2532,"PHASE4":2534,"NA":2536},{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[],{"trials":2527,"activeCount":99},[2528],{"nctId":2504,"briefTitle":2505,"status":364,"phases":2529,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":593,"conditions":2530,"interventions":2531},[89],[2511],[2495,2513],{"trials":2533,"activeCount":99},[],{"trials":2535,"activeCount":99},[],{"trials":2537,"activeCount":99},[],{"intervention":1778,"totalTrials":119,"cells":2539},{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2550,"PHASE4":2552,"NA":2554},{"trials":2541,"activeCount":99},[],{"trials":2543,"activeCount":99},[],{"trials":2545,"activeCount":99},[2546],{"nctId":1770,"briefTitle":1771,"status":364,"phases":2547,"primaryCompletion":1773,"completion":1466,"start":1774,"enrollment":1775,"conditions":2548,"interventions":2549},[89],[15],[1778,1735],{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[],{"trials":2555,"activeCount":99},[],{"intervention":478,"totalTrials":119,"cells":2557},{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2562,"PHASE3":2568,"PHASE4":2570,"NA":2572},{"trials":2559,"activeCount":99},[],{"trials":2561,"activeCount":99},[],{"trials":2563,"activeCount":99},[2564],{"nctId":470,"briefTitle":471,"status":364,"phases":2565,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":2566,"interventions":2567},[89],[18],[478,454,479,480,481,468],{"trials":2569,"activeCount":99},[],{"trials":2571,"activeCount":99},[],{"trials":2573,"activeCount":99},[],{"intervention":479,"totalTrials":119,"cells":2575},{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2586,"PHASE4":2588,"NA":2590},{"trials":2577,"activeCount":99},[],{"trials":2579,"activeCount":99},[],{"trials":2581,"activeCount":99},[2582],{"nctId":470,"briefTitle":471,"status":364,"phases":2583,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":2584,"interventions":2585},[89],[18],[478,454,479,480,481,468],{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"intervention":2593,"totalTrials":119,"cells":2594},"Abatacept plus Aldesleukin",{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2608,"PHASE3":2610,"PHASE4":2612,"NA":2614},{"trials":2596,"activeCount":99},[],{"trials":2598,"activeCount":99},[2599],{"nctId":2600,"briefTitle":2601,"status":125,"phases":2602,"primaryCompletion":2603,"completion":2603,"start":2604,"enrollment":2202,"conditions":2605,"interventions":2607},"NCT06395038","IL-2 Plus Abatacept in FTD",[88],"2026-04-30","2024-05-06",[2606],"Frontotemporal Degeneration",[2593],{"trials":2609,"activeCount":99},[],{"trials":2611,"activeCount":99},[],{"trials":2613,"activeCount":99},[],{"trials":2615,"activeCount":99},[],{"intervention":2617,"totalTrials":119,"cells":2618},"Indocyanine Green",{"EARLY_PHASE1":2619,"PHASE1":2621,"PHASE2":2636,"PHASE3":2638,"PHASE4":2640,"NA":2642},{"trials":2620,"activeCount":99},[],{"trials":2622,"activeCount":99},[2623],{"nctId":2624,"briefTitle":2625,"status":194,"phases":2626,"primaryCompletion":2627,"completion":2627,"start":2628,"enrollment":19,"conditions":2629,"interventions":2635},"NCT02111824","A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy",[88],"2019-11","2014-01-05",[2630,2631,2632,2633,2634],"Lung Neoplasms","Thoracic Neoplasms","Neoplasms by Site","Neoplasms","Lung Diseases",[2617],{"trials":2637,"activeCount":99},[],{"trials":2639,"activeCount":99},[],{"trials":2641,"activeCount":99},[],{"trials":2643,"activeCount":99},[],{"intervention":2645,"totalTrials":119,"cells":2646},"Atezolizumab and Interleukin-12 Gene Therapy",{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2662,"PHASE3":2664,"PHASE4":2666,"NA":2668},{"trials":2648,"activeCount":99},[],{"trials":2650,"activeCount":99},[2651],{"nctId":2652,"briefTitle":2653,"status":194,"phases":2654,"primaryCompletion":2655,"completion":2656,"start":2657,"enrollment":2658,"conditions":2659,"interventions":2661},"NCT04911166","Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy",[88],"2024-08-01","2025-04-01","2021-10-14",13,[2660],"Non-small Cell Lung Cancer",[2645],{"trials":2663,"activeCount":99},[],{"trials":2665,"activeCount":99},[],{"trials":2667,"activeCount":99},[],{"trials":2669,"activeCount":99},[],{"intervention":2671,"totalTrials":119,"cells":2672},"Methadone Hydrochloride",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2689,"PHASE3":2691,"PHASE4":2693,"NA":2695},{"trials":2674,"activeCount":99},[],{"trials":2676,"activeCount":99},[2677],{"nctId":2678,"briefTitle":2679,"status":125,"phases":2680,"primaryCompletion":2681,"completion":2681,"start":2682,"enrollment":2683,"conditions":2684,"interventions":2687},"NCT04112550","Clinical Effectiveness of Pre-operative Methadone in Single Level Lateral Transpsoas Interbody Fusions",[88],"2021-12-31","2020-02-11",150,[2685,2686],"Degenerative Disc Disease","Spondylolisthesis, Lumbar Region",[2671,2688],"Oxycodone-Acetaminophen",{"trials":2690,"activeCount":99},[],{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":99},[],{"trials":2696,"activeCount":99},[],{"intervention":2688,"totalTrials":119,"cells":2698},{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2707,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[2703],{"nctId":2678,"briefTitle":2679,"status":125,"phases":2704,"primaryCompletion":2681,"completion":2681,"start":2682,"enrollment":2683,"conditions":2705,"interventions":2706},[88],[2685,2686],[2671,2688],{"trials":2708,"activeCount":99},[],{"trials":2710,"activeCount":99},[],{"trials":2712,"activeCount":99},[],{"trials":2714,"activeCount":99},[],{"intervention":2716,"totalTrials":119,"cells":2717},"Abatacept Injection [Orencia] and Proleukin",{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2732,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2719,"activeCount":99},[],{"trials":2721,"activeCount":99},[2722],{"nctId":2723,"briefTitle":2724,"status":364,"phases":2725,"primaryCompletion":2726,"completion":2727,"start":2728,"enrollment":25,"conditions":2729,"interventions":2731},"NCT06307301","Study in ALS With Abatacept & IL-2",[88],"2022-12-31","2023-12-31","2021-10-28",[2730],"Amyotrophic Lateral Sclerosis",[2716],{"trials":2733,"activeCount":99},[],{"trials":2735,"activeCount":99},[],{"trials":2737,"activeCount":99},[],{"trials":2739,"activeCount":99},[],{"intervention":2741,"totalTrials":119,"cells":2742},"FDOPA PET",{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[2747],{"nctId":2748,"briefTitle":2749,"status":194,"phases":2750,"primaryCompletion":2751,"completion":2751,"start":2752,"enrollment":1760,"conditions":2753,"interventions":2756},"NCT02176720","Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma",[88],"2016-03","2014-05",[2754,444,2755],"Glioma","Glioblastoma Multiforme",[2741],{"trials":2758,"activeCount":99},[],{"trials":2760,"activeCount":99},[],{"trials":2762,"activeCount":99},[],{"trials":2764,"activeCount":99},[],{"intervention":2766,"totalTrials":119,"cells":2767},"COVID 19 Convalescent Plasma",{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2782,"PHASE3":2784,"PHASE4":2786,"NA":2788},{"trials":2769,"activeCount":99},[],{"trials":2771,"activeCount":99},[2772],{"nctId":2773,"briefTitle":2774,"status":364,"phases":2775,"primaryCompletion":2776,"completion":2776,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2781},"NCT04554992","Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)",[88],"2023-12-20","2020-03-20",350,[2780],"Covid19",[2766],{"trials":2783,"activeCount":99},[],{"trials":2785,"activeCount":99},[],{"trials":2787,"activeCount":99},[],{"trials":2789,"activeCount":99},[],{"intervention":2791,"totalTrials":119,"cells":2792},"Aldesleukin",{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2805,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2794,"activeCount":99},[],{"trials":2796,"activeCount":99},[2797],{"nctId":2798,"briefTitle":2799,"status":364,"phases":2800,"primaryCompletion":2801,"completion":2801,"start":2802,"enrollment":16,"conditions":2803,"interventions":2804},"NCT05821153","Low Dose IL2 Immunotherapy in AD",[88],"2022-04-27","2019-06-19",[29],[2791],{"trials":2806,"activeCount":99},[],{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"trials":2812,"activeCount":99},[],{"intervention":2408,"totalTrials":234,"cells":2814},{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2825,"PHASE4":2827,"NA":2829},{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":99},[],{"trials":2820,"activeCount":99},[2821],{"nctId":2399,"briefTitle":2400,"status":2376,"phases":2822,"primaryCompletion":2402,"completion":2402,"start":2403,"enrollment":99,"conditions":2823,"interventions":2824},[89],[2405,2406],[2390,2408],{"trials":2826,"activeCount":99},[],{"trials":2828,"activeCount":99},[],{"trials":2830,"activeCount":99},[2831],{"nctId":2832,"briefTitle":2833,"status":2376,"phases":2834,"primaryCompletion":1759,"completion":1759,"start":2139,"enrollment":99,"conditions":2835,"interventions":2838},"NCT00109798","Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma",[92],[2836,2837],"Central Nervous System Tumors","Lymphoma",[2839,2840],"temozolomide","topotecan hydrochloride",{"intervention":2842,"totalTrials":119,"cells":2843},"Cardiac MRI taken using contrast agent, Dotarem®",{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2845,"activeCount":99},[],{"trials":2847,"activeCount":99},[],{"trials":2849,"activeCount":99},[],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[2856],{"nctId":2857,"briefTitle":2858,"status":364,"phases":2859,"primaryCompletion":2280,"completion":2860,"start":2861,"enrollment":2862,"conditions":2863,"interventions":2866},"NCT03057561","Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance",[92],"2021-06-30","2016-10-01",120,[2864,2865],"Coronary Artery Disease","Cardiomyopathy",[2842,2867],"Cardiac MRI with contrast agent, Gadovist",{"intervention":2867,"totalTrials":119,"cells":2869},{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2874,"PHASE3":2876,"PHASE4":2878,"NA":2880},{"trials":2871,"activeCount":99},[],{"trials":2873,"activeCount":99},[],{"trials":2875,"activeCount":99},[],{"trials":2877,"activeCount":99},[],{"trials":2879,"activeCount":99},[],{"trials":2881,"activeCount":99},[2882],{"nctId":2857,"briefTitle":2858,"status":364,"phases":2883,"primaryCompletion":2280,"completion":2860,"start":2861,"enrollment":2862,"conditions":2884,"interventions":2885},[92],[2864,2865],[2842,2867],{"intervention":2887,"totalTrials":119,"cells":2888},"Bupivacaine",{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2893,"PHASE3":2895,"PHASE4":2897,"NA":2899},{"trials":2890,"activeCount":99},[],{"trials":2892,"activeCount":99},[],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[],{"trials":2898,"activeCount":99},[],{"trials":2900,"activeCount":99},[2901],{"nctId":2902,"briefTitle":2903,"status":125,"phases":2904,"primaryCompletion":2905,"completion":2906,"start":2907,"enrollment":1409,"conditions":2908,"interventions":2911},"NCT05276258","Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients",[92],"2025-03-15","2025-09-15","2023-02-01",[2909,2910],"Pain","Pain, Postoperative",[2887],{"intervention":2913,"totalTrials":119,"cells":2914},"Intra-detrusor injection of Onabotulinumtoxin-A",{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2921,"PHASE4":2923,"NA":2925},{"trials":2916,"activeCount":99},[],{"trials":2918,"activeCount":99},[],{"trials":2920,"activeCount":99},[],{"trials":2922,"activeCount":99},[],{"trials":2924,"activeCount":99},[],{"trials":2926,"activeCount":99},[2927],{"nctId":2928,"briefTitle":2929,"status":364,"phases":2930,"primaryCompletion":2931,"completion":2931,"start":474,"enrollment":369,"conditions":2932,"interventions":2936},"NCT03033355","Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder",[],"2019-03",[33,2933,24,2934,2935],"Lower Urinary Tract Symptoms","Detrusor, Overactive","Urge Incontinence",[2913],{"intervention":2938,"totalTrials":119,"cells":2939},"Human rabies immune globulin 300 IU\u002FmL",{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2946,"PHASE4":2948,"NA":2950},{"trials":2941,"activeCount":99},[],{"trials":2943,"activeCount":99},[],{"trials":2945,"activeCount":99},[],{"trials":2947,"activeCount":99},[],{"trials":2949,"activeCount":99},[],{"trials":2951,"activeCount":99},[2952],{"nctId":2953,"briefTitle":2954,"status":194,"phases":2955,"primaryCompletion":2956,"completion":2957,"start":2958,"enrollment":2959,"conditions":2960,"interventions":2965},"NCT05382650","Survey of Human Rabies Immune Globulin Safety in Children",[],"2025-09-17","2025-10-15","2023-02-22",35,[2961,2962,2963,2964],"Rabies","Rabies Human","Rabies Virus Infection","Pediatrics",[2938],{"intervention":2840,"totalTrials":119,"cells":2967},{"EARLY_PHASE1":2968,"PHASE1":2970,"PHASE2":2972,"PHASE3":2974,"PHASE4":2976,"NA":2978},{"trials":2969,"activeCount":99},[],{"trials":2971,"activeCount":99},[],{"trials":2973,"activeCount":99},[],{"trials":2975,"activeCount":99},[],{"trials":2977,"activeCount":99},[],{"trials":2979,"activeCount":99},[2980],{"nctId":2832,"briefTitle":2833,"status":2376,"phases":2981,"primaryCompletion":1759,"completion":1759,"start":2139,"enrollment":99,"conditions":2982,"interventions":2983},[92],[2836,2837],[2839,2840],{"intervention":2985,"totalTrials":119,"cells":2986},"Riluzole",{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":2991,"PHASE3":2993,"PHASE4":2995,"NA":2997},{"trials":2988,"activeCount":99},[],{"trials":2990,"activeCount":99},[],{"trials":2992,"activeCount":99},[],{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[],{"trials":2998,"activeCount":99},[2999],{"nctId":3000,"briefTitle":3001,"status":364,"phases":3002,"primaryCompletion":3003,"completion":3004,"start":3005,"enrollment":388,"conditions":3006,"interventions":3008},"NCT00876889","Safety of Riluzole in Patients With Acute Spinal Cord Injury",[],"2011-06","2012-04","2010-04",[3007],"Spinal Cord Injury",[2985]]